Saturday 17 October 2026
Export SIGA’s income statement to Excel — free account
Siga Technologies Inc.
SIGA Healthcare Drug Manufacturers Specialty & Generic
Siga Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $94.6 million, down 31.8% from fiscal 2024. In the quarter to June 2026, revenue fell 49.5%, EPS fell 66.0% and free cash flow fell 76.0%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
3.17
0.02
−0.63%
Follow SIGA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
8.85 | 18.28 | 18.45 | 0.00 |
P/S ratio |
3.80 | 4.62 | 4.09 | 4.87 | |
P/FCF ratio |
5.63 | 10.14 | 13.99 | 0.00 | |
P/Operating CF |
(66.76) | (25.92) | (44.24) | 17.21 | |
P/B ratio |
3.22 | 2.20 | 2.53 | 1.58 | |
Price to Tangible BV |
3.23 | 2.21 | 2.54 | 1.59 | |
EV/Sales |
3.73 | 4.66 | 4.23 | 5.64 | |
EV/EBITDA |
7.07 | 18.18 | 18.70 | 0.00 | |
EV/Operating CF |
5.51 | 10.15 | 14.30 | (15.00) | |
EV/FCF |
5.52 | 10.23 | 14.48 | (14.74) | |
Quick Ratio |
7.02 | 8.79 | 2.30 | 15.90 | |
Current Ratio |
9.17 | 11.83 | 3.25 | 21.72 | |
Net Debt/EBITDA |
17.06 | 16.57 | 28.15 | (8.36) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.81 | 0.41 | 0.40 | 0.26 | |
Operating CF/Net income |
1.54 | 3.11 | 2.51 | 1.22 | |
Capex/Depreciation |
(2.04) | (0.28) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
269.24% | 132.87% | 63.27% | 10.70% | |
Selling, General and Administrative Expense of Revenue |
182.69% | 138.71% | 74.86% | 12.56% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.01 | |
Share Based Compensation of Revenue |
29.55% | 20.36% | 12.06% | 2.95% | |
Graham Net Nets |
0.30 | 0.44 | 0.38 | 0.61 | |
Graham Number |
8.13 | 4.57 | 3.72 | 0.00 | |
Earnings Yield |
11.30% | 5.47% | 5.42% | (1.10%) | |
Free Cash Flow Yield |
17.75% | 9.87% | 7.15% | (7.86%) | |
Revenue per Share |
0.04 | 0.05 | 0.09 | 0.57 | |
Operating CF per Share |
(0.14) | (0.24) | (0.12) | 0.21 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.14) | (0.24) | (0.12) | 0.21 | |
Cash per Share |
2.40 | 2.17 | 2.03 | 1.64 | |
Shareholders Equity per Share |
2.84 | 2.78 | 2.12 | 2.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.84 | 2.78 | 2.12 | 2.30 | |
Free Cash Flow |
(10.10) | (16.90) | (8.66) | 15.17 | |
Working Capital |
202.90 | 194.86 | 146.37 | 162.53 | |
Capital Expenditures |
(0.29) | (0.04) | — | — | |
Net Current Asset Value |
199.62 | 192.21 | 143.76 | 159.93 | |
EV/EBIT |
7.11 | 18.61 | 19.22 | 0.00 | |
Capex to Sales |
0.11 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
7.26 | 18.44 | 18.58 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.29 | 12.21 | 5.84 | 6.83 | |
Average Payables |
3.15 | 1.08 | 3.77 | 1.05 | |
Average Inventory |
55.02 | 49.31 | 57.78 | 38.36 | |
Average Assets |
213.48 | 231.90 | 233.23 | 205.53 | |
Average Common Equity |
186.46 | 207.31 | 183.88 | 187.30 |
Columns are period end dates